Cerebral ischemia, or brain ischemia, is a condition that occurs when there isn’t enough blood supply to meet the metabolic demand of the brain. This results in limited oxygen supply in the brain, or cerebral hypoxia, which leads to the death of brain tissue, cerebral infarction, or an ischemic stroke. This condition is a sub-type of stroke, along with subarachnoid hemorrhage and intracerebral hemorrhage. There are two kinds of ischemia, focal ischemia, and global ischemia.
There are several risk factors involved in brain ischemia, and even other disease complications may lead to the ischemic condition. Heart problems are one among many, and according to the Centers for Disease Control and Prevention, it was estimated that strokes kill approximately 140,000 Americans each year, almost equal to 1 out of every 20 deaths. Each year, more than 795,000 people in the United States have a stroke, and approximately 610,000 of these are new stroke cases.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence